Last updated: July 12, 2026
Executive summary: Glasdegib maleate (brand name: Daurismo) is an oral hedgehog-pathway inhibitor for advanced myeloid malignancies and sits on a constrained addressable market with a high competition burden from other AML targeted therapies. Commercial trajectory is driven by (1) label scope in AML subsets, (2) uptake in combination regimens versus single-agent use, (3) chemotherapy- and transplant-influenced prescribing patterns, and (4) how quickly payers and clinicians move patients to competing pathways (FLT3, IDH1/2, BCL2, venetoclax-based regimens) that often show stronger response rates in defined biomarker groups. Financial performance is also tied to exclusivity cliffs and the timing of generics and biosimilar-like “follow-on” small-molecule competition (non-exclusivity catalysts: salt/formulation changes and generic entry economics), plus any post-approval safety tolerability actions that affect adherence.
What is glasdegib maleate (Daurismo) and what market does it target?
Featured snippet answer: Glasdegib maleate is marketed as Daurismo for AML in combination and/or in specific advanced AML settings. Its commercial market is “niche within AML” rather than broad frontline adoption, with revenue tied to guideline positioning of hedgehog inhibition relative to established low-intensity chemotherapy and venetoclax-based regimens.
Indication coverage that shapes revenue exposure
Glasdegib’s revenue is sensitive to whether it is positioned as:
- a regimen component for older/unfit patients
- a bridge to transplant
- a biomarker-driven niche option
- a fallback therapy after other targeted agents
Because AML care is segmented by fitness and cytogenetic/molecular markers, glasdegib’s usable addressable market depends on its inclusion in local standard-of-care pathways and whether clinicians view it as additive in combination versus replaceable.
How AML prescribing patterns impact adoption
AML treatment pathways commonly move from:
- hypomethylating agents or low-dose cytarabine
- to targeted therapies (IDH1/2, FLT3 inhibitors where applicable)
- often to venetoclax-based regimens when fit and where tolerability permits
- to clinical trials as early lines progress
This means glasdegib’s adoption depends on physicians perceiving a durable incremental benefit in response and survival, plus manageability (myelosuppression, QT prolongation class risks, drug-drug interaction burden).
How is glasdegib maleate positioned versus venetoclax, FLT3 inhibitors, and IDH therapies?
Featured snippet answer: Glasdegib competes indirectly with venetoclax-based low-intensity regimens and more directly with AML targeted agents where patient selection is driven by biomarkers. In practice, it faces substitution risk because many combination slots are already “optimized” to agents with stronger response signals and clearer biomarker governance.
Substitution dynamics in AML
Key competitive forces:
- Venetoclax-based regimens: Often become default “intensification” for older/unfit AML, shifting combination mindshare away from hedgehog-pathway inhibition.
- FLT3 inhibitors: In biomarker-positive patients, targeted therapy can dominate line selection.
- IDH1/2 inhibitors: Similar mechanism-level substitution risk in molecularly defined AML subsets.
- BCL2 and other survival pathway drugs: Further compress the space where a hedgehog inhibitor can win.
Net effect on glasdegib uptake
If clinicians can obtain high response rates with other targeted options or established venetoclax combinations, glasdegib’s share of eligible patients tightens. That drives:
- slower new patient starts
- increased discontinuation during early cycles
- greater payer pushback if clinical differentiation is not compelling in real-world outcomes
What market dynamics drive Daurismo sales growth or decline?
Featured snippet answer: Glasdegib’s sales dynamics hinge on treatment line depth (how long it stays in active use), regimen selection behavior (combination versus monotherapy), and payer coverage in older/unfit AML populations.
Key commercial drivers
- Combination placement: If combinations remain guideline-supported, glasdegib can sustain a steadier base.
- Tolerability management: QT-related monitoring and cytopenias influence adherence and dose continuity.
- Payer reimbursement: Prior authorization and step therapy can blunt volume, especially if prescribers have alternatives in the same class-of-care.
- Evidence maturity: As real-world data accumulates, clinician confidence can either improve or erode, changing persistence.
Key commercial inhibitors
- Rapid line evolution in AML: Patients move quickly to other regimens when response is inadequate.
- Clinical trial displacement: New entrants with stronger data can pull both physicians and payers.
- Economic pressure: AML cost containment measures can reduce uptake for therapies that are harder to justify versus high-penetration regimens.
When does glasdegib maleate lose exclusivity and what are the generic entry risks?
Featured snippet answer: Glasdegib maleate’s exclusivity and patent cliff risk depends on the Orange Book listing for the drug product and the underlying patent family coverage (active ingredient, composition, formulation, and method-of-use). Generic entry timing hinges on whether Paragraph IV challenges are filed against the listed patents and whether any litigation produces a non-expiring settlement or sustained injunction.
Exclusivity categories that matter for small-molecule oncology drugs
For a drug like glasdegib maleate, typical “cliff” drivers include:
- Patent expiration dates for active ingredient and formulation claims.
- Regulatory exclusivities (5-year/3-year scheme if applicable to the approval history).
- Orange Book-controlled method-of-use claims (if listed).
- Salt-specific and polymorph coverage (sometimes controls “follow-on” generic attempts).
Generic entry risk map
Generic entry risk usually concentrates where:
- formulation/process patents are weak or expire sooner than the composition claims
- litigation settlements allow “carve-out” launch dates
- regulatory exclusivity does not extend beyond patent cliffs
- ANDA pathways are feasible without infringing listed claims
What is the Orange Book status of glasdegib maleate (Daurismo)?
Featured snippet answer: Orange Book status determines the number and type of listed patents tied to the NDA, including drug substance, drug product, and method-of-use patents. That list is the direct basis for Paragraph IV strategy and “skinny label” viability.
How Orange Book listings translate to commercial timelines
- More listed patents typically means more opportunities for ANDA challenges but also more litigation probability.
- Method-of-use claims can delay generic launch even when chemical composition patents are expiring.
- Formulation and manufacturing patents can require process redesign or can create “launch inhibitors” even after earliest expiration.
(No Orange Book patent listing content is reproduced here because the required Orange Book dataset for glasdegib maleate is not provided in the prompt.)
How strong is the patent estate for glasdegib maleate and what formulations are protected?
Featured snippet answer: For oncology small molecules, the strongest estate elements tend to be drug substance composition claims, solid-state and polymorph claims (if any), and dosage-form or combination-regimen method-of-use claims. The “weak link” for exclusivity often sits in late-introduced formulation patents if they are narrow.
Patent estate components that usually drive value
- Drug substance: synthesis intermediates and final compound claims tied to glasdegib.
- Drug product: tablets/capsules and excipient systems that support stability and dissolution.
- Salt and solid-state: coverage for the maleate salt form, including polymorphs.
- Method-of-use: regimen instructions tied to AML settings and combination partners.
Why formulation matters for generic timelines
If the maleate salt has specific solid-state attributes, generics may need to match or prove non-infringement by using alternate forms. That can:
- delay launch due to reformulation work
- increase costs and regulatory bridge studies
- trigger additional patent barriers via narrow but enforceable claims
Which companies are challenging glasdegib maleate and what patent litigation affects market entry?
Featured snippet answer: ANDA challengers and the resulting litigation determine whether exclusivity is extended via court injunctions or shortened via settlements. Litigation also influences payer confidence and clinician trust if a court ruling accelerates access.
(No challenger names, case captions, or litigation dates are provided in the prompt, so a complete and accurate litigation map cannot be constructed.)
How do settlement agreements affect glasdegib maleate generic launch timing?
Featured snippet answer: Settlement agreements can lock in a launch delay or permit an earlier at-risk entry based on the scope of dismissed or licensed patents. The commercial effect is immediate through:
- reduced uncertainty for wholesalers and payers
- modified contracting terms for future pricing
- accelerated retailer-level forecast changes once launch dates are set
(Settlement data requires case-specific information not included in the prompt.)
What FDA regulatory milestones and label scope changes affect revenue?
Featured snippet answer: Revenue shifts occur when label expansions broaden eligible patients, when safety updates change monitoring requirements, or when regulatory communications alter combination usage.
Milestones that move sales curves
- approval and subsequent supplemental approvals that broaden AML patient subsets
- safety communications tied to risk mitigation
- changes in recommended dosing, monitoring, or drug interaction guidance
Pathway and real-world implications
Even without new indications, label clarity can affect:
- inclusion in hospital formularies
- compliance in community oncology
- insurance coverage decisions
How does glasdegib maleate compare with competing AML oral oncology assets on commercialization metrics?
Featured snippet answer: Small-molecule oral AML therapies compete on net patient starts, persistence, and ability to secure payers. A therapy’s commercialization advantage comes from clinical differentiation strong enough to overcome venetoclax’s market gravity and from manageable monitoring requirements.
Competitive comparison framework
For each comparator, evaluate:
- targeted biomarker exclusivity versus broader eligibility
- line placement incentives (second-line versus frontline)
- combination standard-of-care fit
- safety monitoring intensity
- generic pipeline headwinds (patent cliffs)
(No specific competitor-by-competitor metrics are provided in the prompt.)
What is the financial trajectory for glasdegib maleate: revenue, growth, and impairment drivers?
Featured snippet answer: Glasdegib’s financial trajectory is shaped less by broad market scaling and more by sustained patient starts in a limited AML segment and by how quickly payer and clinician adoption is displaced by venetoclax-based regimens and other targeted therapies. Once exclusivity approaches, pricing pressure and volume erosion typically accelerate.
What to watch in quarterly reporting
The following items are usually the highest-signal for trajectory:
- total net product revenue trends and regional mix
- prescription and patient persistence indicators (if disclosed)
- gross-to-net changes from rebates and contracting
- commercialization cost growth versus sales base
- inventory adjustments and charge impacts from channel fill and demand forecasting
(No company financial statements, sales figures, or reported revenue trend data is included in the prompt.)
How do exclusivity timelines and price erosion typically play out for a small-molecule oncology asset like glasdegib?
Featured snippet answer: Patent expiration and regulatory exclusivity expiry create a “two-stage” erosion pattern: first, expectations of generic entry trigger contracting and formulary shifts; second, actual launch volumes and price cuts materially compress net pricing.
Commercial timeline mechanics
- 12 to 36 months pre-expiration: proactive contracting and payer scrutiny increases; wholesalers adjust forecasting.
- Launch window: at-risk or approved generic entry changes net pricing quickly.
- Post-launch: subsequent additional filings can further erode price and volume.
Key Takeaways
- Glasdegib maleate (Daurismo) competes in AML within a constrained and highly substitutable treatment ecosystem where venetoclax and biomarker-driven targeted therapies often set prescribing defaults.
- Market dynamics depend on combination uptake, tolerability-driven persistence, and payer coverage rather than on broad frontline adoption.
- Generic entry risk is governed by Orange Book-listed patents and whether challengers file Paragraph IV certifications with successful litigation outcomes or settlement-triggered launch dates.
- Patent estate strength typically concentrates in drug substance, maleate salt/solid-state protection, drug product formulation, and method-of-use claims; the narrowness and expiration sequencing of these elements drives exclusivity duration and timing of price erosion.
- Financial trajectory is driven by sustained patient starts and net pricing resilience up to exclusivity cliffs, followed by contracting pressure and volume erosion once launch becomes credible.
FAQs
-
What drives real-world persistence for glasdegib maleate in AML?
Dose continuity, QT monitoring adherence, cytopenia management, and regimen tolerability in combination use.
-
Does glasdegib maleate face more competition from oral AML targeted therapies or from venetoclax-based regimens?
Both, but venetoclax-based low-intensity regimens often create the fastest substitution pressure because they function as default combination “intensification” for many unfit patients.
-
What is the main patent barrier for generic manufacturers of glasdegib maleate?
Orange Book-listed method-of-use and drug product/formulation or solid-state claims tied to the NDA.
-
How do payer restrictions typically affect glasdegib maleate uptake?
Step therapy and prior authorization can delay or reduce patient starts if comparable covered regimens exist with stronger perceived differentiation.
-
What indicators show generic entry risk is rising before exclusivity expiry?
Increased contracting conservatism, formulary repositioning, and disclosures in litigation filings or settlement talks that crystallize potential launch timelines.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Access required for glasdegib maleate listings).
- FDA. Drug Approval Packages and Labeling for Daurismo (glasdegib). (Access required for specific milestones and label scope).
- FDA. NDA approval history and supplemental approval records for glasdegib maleate. (Access required for exact timeline).
